Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trialBruce E. Sands, Olga Fedorishina, Long-Long Gao et al.|The Lancet|2022Cited by 295
Development of a core outcome set for therapeutic studies in eosinophilic esophagitis (COREOS)Christopher Ma, Philip E. Putnam, Alain Schoepfer et al.|Journal of Allergy and Clinical Immunology|2021Cited by 82